Patrycja Dubielecka-Szczerba Assistant Professor of Medicine (Research)

Dr. Dubielecka is an Assistant Professor of Medicine at the Alpert Medical School of Brown University and head of the Signal Transduction Lab. She also holds an adjunct appointment in the Division of Hematology/Oncology in the Department of Medicine at Rhode Island Hospital. Dr. Dubielecka received her undergraduate and PhD degrees from the University of Wroclaw, Poland. She was a scholar of the Socrates/Erasmus Programme established by the European Commission, and trained at the University of Helsinki, Finland and at Charles University in Hradec Kralove, Czech Republic. Dr. Dubielecka did her postdoctoral training in the Lindsley F. Kimball Research Institute in New York. During her training she collaborated closely with colleagues at the University of Michigan, Ann Arbor and Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany. Dr. Dubielecka received extensive training in biochemistry, biophysics, cell biology, and protein chemistry. Prior to joining the faculty at Brown University, Dr. Dubielecka was a project leader in the NIH Center of Biomedical Research Excellence (COBRE) in Stem Cell Biology at the Roger Williams Medical Center, Boston University School of Medicine. Dr. Dubielecka has mentored undergraduate students, medical students, residents, fellows, and post-doctoral fellows.

Brown Affiliations

Research Areas

scholarly work

Michalczyk I, Sikorski AF, Kotula L, Junghans RP, Dubielecka PM. The emerging role of PKCθ in cytoskeletal signal transduction. J Leukoc Biol. 2013 Mar;93(3):319-27.

Bartos A, Dubielecka PM. Cytoskeletal response to Bcr-Abl and its emerging role in systemic persistence of leukemic stem cells. Curr Drug Deliv. 2013 Mar 18.

Toporkiewicz M, Michalczyk I, Grzybek M, Dubielecka PM, Korycka J, Seweryn E, Sikorski AF. Release of a 55 kDa fragment containing the actin-binding domain of β-spectrin by caspase 8 during FND induced apoptosis depends on the presence of protein 4.1 Arch Biochem Biophys. 2013 Jul 15;535(2):205-13.

Xiong X, Chorzalska A, Dubielecka PM, White J, Vedvyas Y, Hedvat CV, Haimovitz-Friedman A, Koutcher JA, Reimand J, Bader G, Sawicki JA, Kotula L. Disruption of Abi1/Hssh3bp1 expression induces prostatic intraepithelial neoplasia in the conditional Abi1/Hssh3bp1 KO mice. Oncogenesis 2012, 1, e26.

Hossain S, Dubielecka PM, Sikorski AF, Birge RB, Kotula L. Crk and Abi1: Binary molecular switches that regulate Abl tyrosine kinase and signaling to the cytoskeleton. Genes Cancer. 2012 May;3(5-6):402-13.

Zhang L, Qin X, Chen B, Zhao Y, Dubielecka PM, Lei Wei, Qin JG, Zhao TC. Inhibition of histone deacetylases-induced myocardial repair is mediated by c-kit in infarcted hearts. J Biol Chem. 2012 Nov 16;287(47):39338-48.

Dubielecka PM, Hwynn N, Sengun C, Lee S, Lomas-Francis C, Singer C, Fernandez HH, Walker RH. Two McLeod patients with novel mutations in XK. J Neurol Sci. 2011 Jun 15;305(1-2):160-4.

Dubielecka PM, Ladwein KI, Xiong X, Migeotte I, Chorzalska A, Anderson KV, Sawicki JA, Rottner K, Stradal TE, Kotula L. Essential role for Abi1 in embryonic survival and WAVE2 complex integrity. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7022-7.

Dubielecka PM, Grzybek M, Kolondra A, Jazwiec B, Draga A, Aleksandrowicz P, Kolodziejczyk M, Dolinska-Krajewska B, Warchol J, Kuliczkowski K and Sikorski AF. Aggregation of spectrin and PKCθ is an early hallmark of fludarabine/mitoxantrpoe/dexamethasone-induced apoptosis in Jurkat T and HL60 cells. Mol Cell Biochem. 2010 Jun;339(1-2):63-77.

Dubielecka PM, Cui P, Xiong X, Hossain S, Heck S, Angelov L, Kotula L. Differential regulation of macropinocytosis by Abi1/Hssh3bp1 isoforms. PLoS One. 2010 May 10;5(5):e10430.

Dubielecka PM, Machida K, Xiong X, Hossain S, Ogiue-Ikeda M, Carrera AC, Mayer BJ, Kotula L. Abi1/Hssh3bp1 pY213 links Abl kinase signaling to p85 regulatory subunit of PI-3 kinase in regulation of macropinocytosis in LNCaP cells. FEBS Lett. 2010 Aug 4;584(15):3279-3286.

Bok E, Plazuk E, Hryniewicz-Jankowska A, Chorzalska A, Szmaj A, Dubielecka PM, Stebelska K, Diakowski W, Lisowski M, Langner M, Sikorski AF. Lipid-binding role of betaII-spectrin ankyrin-binding domain. Cell Biol Int. 2007 Dec;31(12):1482-94.

Dubielecka PM, Trusz A Diakowski W, Grzybek M, Chorzalska A, Jazwiec B, Lisowski M, Jezierski A, Sikorski AF. Mitoxantrone changes spectrin-aminophospholipid interactions. Mol Membr Biol, 2006; 23(3):1-9.

Grzybek M, Kozubek A, Dubielecka PM, Sikorski AF. Rafts – the Current Picture. Folia Histochem Cytobiol. 2005; 43(1):3-10.

Stebelska K, Dubielecka PM, Sikorski AF. The effect of PS content on the ability of natural membranes to fuse with positively charged liposomes and lipoplexes. J Membr Biol. 2005; 206(3):203-14.

Dubielecka PM, Jazwiec B, Potoczek S, Wrobel T, Miloszewska J, Haus O, Kuliczkowski K, Sikorski AF. Changes in spectrin organisation in leukaemic and lymphoid cells upon chemotherapy. Biochem Pharmacol. 2005; 69(1):73-85.

Hryniewicz-Jankowska A, Bok E, Dubielecka PM, Chorzalska A, Diakowski W, Jezierski A, Lisowski M, Sikorski AF. Mapping of an ankyrin-sensitive, phosphatidylethanolamine/ phosphatidylcholine mono- and bi-layer binding site in erythroid beta-spectrin. Biochem J. 2004; 382(2):677-85.

Dubielecka PM, Stebelska K, Jazwiec B, Sikorski AF. Cystocyte and lymphocyte derived fusomes/spectrosomes: analogies and differences: a mini-review. Cell Mol Biol Lett. 2003; 8(1):221-9.

Zhao H, Dubielecka PM, Soderlund T, Kinnunen PK. Interactions of adriamycin, cytochrome c, and serum albumin with lipid monolayers containing poly(ethylene glycol)-ceramide. Biophys J. 2002; 83(2):954-67.

Dubielecka P, Potoczek S, Jazwiec B, Miloszewska J, Kuliczkowski K, Sikorski AF. The Effect Of Chemotherapy With Fludarabine/Mitoxantrone/Dexamethasone On The Distribution Of Spectrin In Lymphocytes Of Non-Hodgkin Lymphoma Patients. Cell Mol Biol Lett. 2001;6(2):200.

research overview

Specific niches within the bone marrow microenvironment allow subpopulations of leukemic stem cells (LSCs) to evade chemotherapy, providing a reservoir of drug resistant LSCs. Eradication of these cells possesses a major challenge to the development of curative treatment for CML and other types of leukemia. Our approach to meeting this challenge is aimed at understanding the molecular characteristics of the interactions between leukemic stem cells and the bone marrow microenvironment. The goal of our research is to identify new targets for therapies aimed at eradicating drug resistant leukemic stem cells responsible for relapse.